Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
88.10
-3.07 (-3.37%)
May 5, 2026, 11:51 AM EDT - Market open
Guardant Health Employees
As of December 31, 2025, Guardant Health had 2,506 total employees, including 2,490 full-time and 16 part-time employees. The number of employees increased by 485 or 24.00% compared to the previous year.
Employees
2,506
Change (1Y)
485
Growth (1Y)
24.00%
Revenue / Employee
$391,868
Profits / Employee
-$166,112
Market Cap
11.56B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 2,506 | 485 | 24.00% | 2,490 | 16 |
| Dec 31, 2024 | 2,021 | 242 | 13.60% | 1,999 | 22 |
| Dec 31, 2023 | 1,779 | -14 | -0.78% | 1,768 | 11 |
| Dec 31, 2022 | 1,793 | 420 | 30.59% | 1,793 | 0 |
| Dec 31, 2021 | 1,373 | 509 | 58.91% | 1,373 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IQVIA Holdings | 93,000 |
| Labcorp Holdings | 71,000 |
| Quest Diagnostics | 57,000 |
| ICON Public Limited Company | 41,900 |
| Charles River Laboratories International | 19,700 |
| Mettler-Toledo International | 18,100 |
| Revvity | 11,000 |
| Illumina | 10,080 |
GH News
- 1 day ago - Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations - Business Wire
- 5 days ago - Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform - Business Wire
- 5 days ago - Guardant Health to Participate in Upcoming Investor Conferences - Business Wire
- 6 days ago - Why Is Guardant Health Stock Falling On Tuesday? - Benzinga
- 18 days ago - Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026 - Business Wire
- 5 weeks ago - Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan - Business Wire
- 6 weeks ago - Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data - PRNewsWire
- 6 weeks ago - Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 - Business Wire